25 XP   0   0   10

Viridian Therapeutics Inc
Buy, Hold or Sell?

Let's analyse Viridian Therapeutics Inc together

PenkeI guess you are interested in Viridian Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Viridian Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Viridian Therapeutics Inc

I send you an email if I find something interesting about Viridian Therapeutics Inc.

Quick analysis of Viridian Therapeutics Inc (30 sec.)










What can you expect buying and holding a share of Viridian Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
5.0%

What is your share worth?

Current worth
$7.04
Expected worth in 1 year
$7.79
How sure are you?
27.5%

+ What do you gain per year?

Total Gains per Share
$0.75
Return On Investment
5.1%

For what price can you sell your share?

Current Price per Share
$14.60
Expected price per share
$9.87 - $19.07
How sure are you?
50%

1. Valuation of Viridian Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)

$14.60

Intrinsic Value Per Share

$-34.64 - $-16.61

Total Value Per Share

$-27.60 - $-9.57

2. Growth of Viridian Therapeutics Inc (5 min.)




Is Viridian Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$442m$278.1m$69.8m20.1%

How much money is Viridian Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$59.4m-$31.3m-$28m-47.2%
Net Profit Margin-76,241.7%-16,530.2%--

How much money comes from the company's main activities?

3. Financial Health of Viridian Therapeutics Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#125 / 1016

Most Revenue
#644 / 1016

Most Profit
#913 / 1016

Most Efficient
#993 / 1016

What can you expect buying and holding a share of Viridian Therapeutics Inc? (5 min.)

Welcome investor! Viridian Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of Viridian Therapeutics Inc.

What can you expect buying and holding a share of Viridian Therapeutics Inc?

First you should know what it really means to hold a share of Viridian Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Viridian Therapeutics Inc is $14.60. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Viridian Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Viridian Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $7.04. Based on the TTM, the Book Value Change Per Share is $0.19 per quarter. Based on the YOY, the Book Value Change Per Share is $0.83 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Viridian Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-1.07-7.3%-0.95-6.5%-0.52-3.5%-0.48-3.3%-0.28-1.9%
Usd Book Value Change Per Share2.5217.3%0.191.3%0.835.7%0.312.1%0.181.2%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share2.5217.3%0.191.3%0.835.7%0.312.1%0.181.2%
Usd Price Per Share21.78-21.59-19.95-13.11-8.89-
Price to Earnings Ratio-5.11--5.70--9.65--6.92--11.18-
Price-to-Total Gains Ratio8.63--25.03--52.77--51.52--85.77-
Price to Book Ratio3.09-3.94-4.97-4.80--15.41-
Price-to-Total Gains Ratio8.63--25.03--52.77--51.52--85.77-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share14.6
Number of shares68
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.190.31
Usd Total Gains Per Share0.190.31
Gains per Quarter (68 shares)12.7221.16
Gains per Year (68 shares)50.8784.65
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10514108575
20102920169160
301531430254245
402031940339330
502542450423415
603052960508500
703563470593585
804073980677670
904584490762755
1005095000846840

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.040.00.00.0%0.044.00.00.0%
Book Value Change Per Share1.03.00.025.0%3.09.00.025.0%5.015.00.025.0%10.030.00.025.0%11.030.03.025.0%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%2.00.038.05.0%6.00.038.013.6%
Total Gains per Share1.03.00.025.0%3.09.00.025.0%5.015.00.025.0%11.029.00.027.5%15.029.00.034.1%

Fundamentals of Viridian Therapeutics Inc

About Viridian Therapeutics Inc

Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

Fundamental data was last updated by Penke on 2024-04-09 09:09:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Viridian Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Viridian Therapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Viridian Therapeutics Inc to the Biotechnology industry mean.
  • A Net Profit Margin of -92,861.1% means that $-928.61 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Viridian Therapeutics Inc:

  • The MRQ is -92,861.1%. The company is making a huge loss. -2
  • The TTM is -76,241.7%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-92,861.1%TTM-76,241.7%-16,619.5%
TTM-76,241.7%YOY-16,530.2%-59,711.5%
TTM-76,241.7%5Y-28,668.7%-47,573.0%
5Y-28,668.7%10Y-14,615.4%-14,053.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-92,861.1%-199.6%-92,661.5%
TTM-76,241.7%-213.0%-76,028.7%
YOY-16,530.2%-279.3%-16,250.9%
5Y-28,668.7%-438.4%-28,230.3%
10Y-14,615.4%-605.5%-14,009.9%
1.1.2. Return on Assets

Shows how efficient Viridian Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Viridian Therapeutics Inc to the Biotechnology industry mean.
  • -13.6% Return on Assets means that Viridian Therapeutics Inc generated $-0.14 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Viridian Therapeutics Inc:

  • The MRQ is -13.6%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -15.3%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-13.6%TTM-15.3%+1.7%
TTM-15.3%YOY-11.8%-3.5%
TTM-15.3%5Y-19.4%+4.0%
5Y-19.4%10Y-21.7%+2.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-13.6%-13.5%-0.1%
TTM-15.3%-12.9%-2.4%
YOY-11.8%-11.8%0.0%
5Y-19.4%-14.1%-5.3%
10Y-21.7%-16.0%-5.7%
1.1.3. Return on Equity

Shows how efficient Viridian Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Viridian Therapeutics Inc to the Biotechnology industry mean.
  • -15.1% Return on Equity means Viridian Therapeutics Inc generated $-0.15 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Viridian Therapeutics Inc:

  • The MRQ is -15.1%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -17.2%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-15.1%TTM-17.2%+2.1%
TTM-17.2%YOY-13.4%-3.8%
TTM-17.2%5Y-25.5%+8.3%
5Y-25.5%10Y-24.4%-1.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-15.1%-16.9%+1.8%
TTM-17.2%-16.1%-1.1%
YOY-13.4%-15.1%+1.7%
5Y-25.5%-19.9%-5.6%
10Y-24.4%-20.9%-3.5%

1.2. Operating Efficiency of Viridian Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Viridian Therapeutics Inc is operating .

  • Measures how much profit Viridian Therapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Viridian Therapeutics Inc to the Biotechnology industry mean.
  • An Operating Margin of -91,588.9% means the company generated $-915.89  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Viridian Therapeutics Inc:

  • The MRQ is -91,588.9%. The company is operating very inefficient. -2
  • The TTM is -78,279.7%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-91,588.9%TTM-78,279.7%-13,309.2%
TTM-78,279.7%YOY-18,189.0%-60,090.7%
TTM-78,279.7%5Y-22,919.3%-55,360.4%
5Y-22,919.3%10Y-11,735.2%-11,184.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-91,588.9%-295.1%-91,293.8%
TTM-78,279.7%-225.8%-78,053.9%
YOY-18,189.0%-288.4%-17,900.6%
5Y-22,919.3%-477.4%-22,441.9%
10Y-11,735.2%-625.6%-11,109.6%
1.2.2. Operating Ratio

Measures how efficient Viridian Therapeutics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 998.61 means that the operating costs are $998.61 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Viridian Therapeutics Inc:

  • The MRQ is 998.611. The company is inefficient in keeping operating costs low. -1
  • The TTM is 822.146. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ998.611TTM822.146+176.465
TTM822.146YOY281.283+540.863
TTM822.1465Y257.608+564.538
5Y257.60810Y132.004+125.604
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ998.6113.090+995.521
TTM822.1463.264+818.882
YOY281.2833.783+277.500
5Y257.6085.679+251.929
10Y132.0047.894+124.110

1.3. Liquidity of Viridian Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Viridian Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 18.26 means the company has $18.26 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Viridian Therapeutics Inc:

  • The MRQ is 18.265. The company is very able to pay all its short-term debts. +2
  • The TTM is 14.229. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ18.265TTM14.229+4.036
TTM14.229YOY12.579+1.650
TTM14.2295Y9.838+4.391
5Y9.83810Y8.482+1.356
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ18.2653.914+14.351
TTM14.2294.220+10.009
YOY12.5795.388+7.191
5Y9.8386.045+3.793
10Y8.4826.406+2.076
1.3.2. Quick Ratio

Measures if Viridian Therapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Viridian Therapeutics Inc to the Biotechnology industry mean.
  • A Quick Ratio of 31.99 means the company can pay off $31.99 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Viridian Therapeutics Inc:

  • The MRQ is 31.989. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 24.175. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ31.989TTM24.175+7.813
TTM24.175YOY19.325+4.850
TTM24.1755Y15.093+9.082
5Y15.09310Y11.357+3.736
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ31.9893.572+28.417
TTM24.1753.998+20.177
YOY19.3255.390+13.935
5Y15.0935.969+9.124
10Y11.3576.287+5.070

1.4. Solvency of Viridian Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Viridian Therapeutics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Viridian Therapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.10 means that Viridian Therapeutics Inc assets are financed with 9.9% credit (debt) and the remaining percentage (100% - 9.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Viridian Therapeutics Inc:

  • The MRQ is 0.099. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.108. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.099TTM0.108-0.009
TTM0.108YOY0.105+0.003
TTM0.1085Y0.194-0.086
5Y0.19410Y0.232-0.038
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0990.336-0.237
TTM0.1080.334-0.226
YOY0.1050.269-0.164
5Y0.1940.366-0.172
10Y0.2320.390-0.158
1.4.2. Debt to Equity Ratio

Measures if Viridian Therapeutics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Viridian Therapeutics Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 11.0% means that company has $0.11 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Viridian Therapeutics Inc:

  • The MRQ is 0.110. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.121. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.110TTM0.121-0.012
TTM0.121YOY0.119+0.003
TTM0.1215Y0.278-0.157
5Y0.27810Y0.291-0.013
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1100.382-0.272
TTM0.1210.396-0.275
YOY0.1190.335-0.216
5Y0.2780.434-0.156
10Y0.2910.465-0.174

2. Market Valuation of Viridian Therapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Viridian Therapeutics Inc generates.

  • Above 15 is considered overpriced but always compare Viridian Therapeutics Inc to the Biotechnology industry mean.
  • A PE ratio of -5.11 means the investor is paying $-5.11 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Viridian Therapeutics Inc:

  • The EOD is -3.427. Based on the earnings, the company is expensive. -2
  • The MRQ is -5.112. Based on the earnings, the company is expensive. -2
  • The TTM is -5.700. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.427MRQ-5.112+1.685
MRQ-5.112TTM-5.700+0.588
TTM-5.700YOY-9.649+3.949
TTM-5.7005Y-6.923+1.223
5Y-6.92310Y-11.175+4.252
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-3.427-2.259-1.168
MRQ-5.112-2.569-2.543
TTM-5.700-2.664-3.036
YOY-9.649-4.120-5.529
5Y-6.923-6.258-0.665
10Y-11.175-6.171-5.004
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Viridian Therapeutics Inc:

  • The EOD is -6.021. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -8.983. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -7.430. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-6.021MRQ-8.983+2.961
MRQ-8.983TTM-7.430-1.553
TTM-7.430YOY-13.106+5.676
TTM-7.4305Y-10.404+2.974
5Y-10.40410Y-20.751+10.347
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-6.021-2.924-3.097
MRQ-8.983-3.246-5.737
TTM-7.430-3.488-3.942
YOY-13.106-5.620-7.486
5Y-10.404-8.315-2.089
10Y-20.751-8.826-11.925
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Viridian Therapeutics Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 3.09 means the investor is paying $3.09 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Viridian Therapeutics Inc:

  • The EOD is 2.073. Based on the equity, the company is underpriced. +1
  • The MRQ is 3.093. Based on the equity, the company is fair priced.
  • The TTM is 3.943. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD2.073MRQ3.093-1.020
MRQ3.093TTM3.943-0.850
TTM3.943YOY4.968-1.025
TTM3.9435Y4.803-0.860
5Y4.80310Y-15.411+20.214
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.0731.851+0.222
MRQ3.0932.090+1.003
TTM3.9432.095+1.848
YOY4.9682.844+2.124
5Y4.8033.466+1.337
10Y-15.4113.815-19.226
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Viridian Therapeutics Inc.

3.1. Institutions holding Viridian Therapeutics Inc

Institutions are holding 101.146% of the shares of Viridian Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31FMR Inc12.14890.0128762554273633542808.4253
2023-12-31Paradigm Biocapital Advisors LP7.63854.88894794488111274130.2232
2023-12-31Deep Track Capital, LP5.7862.6416363172866846122.5582
2023-12-31BlackRock Inc5.45890.0019342645043338714.4797
2023-09-30VR Adviser, LLC4.91124.9779308262200
2023-12-31Vanguard Group Inc4.7810.0014300094855293322.587
2023-12-31State Street Corporation4.31490.00292708383-233307-7.9311
2023-12-31Maverick Capital Ltd3.70551.0173232584123258410
2023-12-31AllianceBernstein L.P.3.28110.017320594641684668.9088
2023-12-31COMMODORE CAPITAL LP3.06543.66171924074-275926-12.5421
2023-09-30BRAIDWELL LP2.76450.8412173518252888243.8433
2023-12-31Perceptive Advisors LLC2.75650.8412173021271900771.104
2023-12-31Vivo Capital, LLC2.67372.9928167820700
2023-12-31Fairmount Funds Management LLC2.18213.1518136962300
2023-12-31Yiheng Capital LLC1.95731.5424122853400
2023-09-30Octagon Capital Advisors LP1.70022.515106714314414315.6168
2023-12-31Pictet Asset Manangement SA1.67420.02521050876-15467-1.4505
2023-12-31Vestal Point Capital LP1.59322.3073100000010000000
2023-12-31Geode Capital Management, LLC1.58440.002399446813537315.7576
2023-12-31Polar Capital Holdings PLC1.56120.1308979917-620083-38.7552
Total 75.538731.573747413702+14007805+29.5%

3.2. Funds holding Viridian Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-03-28SPDR® S&P Biotech ETF5.70350.793406660429601.2772
2024-02-29Vanguard Total Stock Mkt Idx Inv2.98410.0022178238900
2024-02-29Fidelity Advisor Biotechnology I2.15121.3519128490700
2024-03-28iShares Russell 2000 ETF2.03360.032512146455850.0482
2024-02-29Fidelity Select Health Care1.97560.2789118000000
2024-02-29Fidelity Select Biotechnology1.73990.39551039238-7829-0.7477
2024-02-29Polar Capital Biotech S Inc1.67421.0641000000892819.8034
2024-02-29AB Small Cap Growth A1.56370.4348933984-23821-2.487
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.3670.015816470-899-0.11
2024-01-31Fidelity Small Cap Growth1.31130.26378320016160025.9974
2024-01-31Fidelity Series Small Cap Opps1.29690.2882774652281003.764
2024-02-29Fidelity Advisor Health Care I1.25570.28275000000
2024-01-31FIAM Small Cap Core CIT Cl B1.21880.369772800000
2023-12-31FIAM Small Cap Core Composite1.21880.40617280007280000
2024-02-29Strategic Advisers Fidelity US TtlStk1.01710.0108607500251004.3098
2023-12-31Pictet-Biotech P USD0.94970.7822567263104261.8724
2024-01-31CREF Stock R10.90740.00885419705419700
2024-01-31Fidelity Small Cap Index0.7220.033543126562541.4715
2024-03-31Direxion Daily S&P Biotech Bull 3X ETF0.68460.5733408887-2869-0.6968
2024-01-31Fidelity Stock Selector Small Cap0.67290.292401927249006.6043
Total 32.4487.674419380957+1623758+8.4%

3.3. Insider Transactions

Insiders are holding 1.021% of the shares of Viridian Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-01-22Fairmount Funds Management LlcBUY47619021
2023-06-15Lara MeisnerSELL226928.02
2023-06-05Lara MeisnerSELL49925.03
2023-06-02Lara MeisnerSELL187524.21
2023-04-12Scott Dunseth MyersBUY400025.37

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Viridian Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--2.5240.187+1250%0.826+206%0.311+711%0.175+1340%
Book Value Per Share--7.0425.544+27%4.431+59%2.712+160%1.559+352%
Current Ratio--18.26514.229+28%12.579+45%9.838+86%8.482+115%
Debt To Asset Ratio--0.0990.108-8%0.105-6%0.194-49%0.232-57%
Debt To Equity Ratio--0.1100.121-10%0.119-8%0.278-61%0.291-62%
Dividend Per Share----0%-0%-0%0.002-100%
Eps---1.065-0.947-11%-0.517-51%-0.478-55%-0.275-74%
Free Cash Flow Per Share---0.606-0.737+22%-0.377-38%-0.319-47%-0.188-69%
Free Cash Flow To Equity Per Share--2.5630.162+1485%0.907+183%0.298+760%0.166+1448%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.049-5%
Intrinsic Value_10Y_max---16.608--------
Intrinsic Value_10Y_min---34.638--------
Intrinsic Value_1Y_max---0.887--------
Intrinsic Value_1Y_min---2.078--------
Intrinsic Value_3Y_max---3.256--------
Intrinsic Value_3Y_min---7.487--------
Intrinsic Value_5Y_max---6.341--------
Intrinsic Value_5Y_min---14.218--------
Market Cap916406960.000-49%1367078328.0001354995565.000+1%1251899782.000+9%822826745.160+66%558178301.009+145%
Net Profit Margin---928.611-762.417-18%-165.302-82%-286.687-69%-146.154-84%
Operating Margin---915.889-782.797-15%-181.890-80%-229.193-75%-117.352-87%
Operating Ratio--998.611822.146+21%281.283+255%257.608+288%132.004+657%
Pb Ratio2.073-49%3.0933.943-22%4.968-38%4.803-36%-15.411+598%
Pe Ratio-3.427+33%-5.112-5.700+12%-9.649+89%-6.923+35%-11.175+119%
Price Per Share14.600-49%21.78021.588+1%19.945+9%13.109+66%8.893+145%
Price To Free Cash Flow Ratio-6.021+33%-8.983-7.430-17%-13.106+46%-10.404+16%-20.751+131%
Price To Total Gains Ratio5.784-49%8.628-25.028+390%-52.774+712%-51.516+697%-85.768+1094%
Quick Ratio--31.98924.175+32%19.325+66%15.093+112%11.357+182%
Return On Assets---0.136-0.153+13%-0.118-13%-0.194+42%-0.217+59%
Return On Equity---0.151-0.172+14%-0.134-11%-0.255+69%-0.244+62%
Total Gains Per Share--2.5240.187+1250%0.826+206%0.311+711%0.178+1321%
Usd Book Value--442022000.000348001000.000+27%278152750.000+59%170219900.000+160%97838557.425+352%
Usd Book Value Change Per Share--2.5240.187+1250%0.826+206%0.311+711%0.175+1340%
Usd Book Value Per Share--7.0425.544+27%4.431+59%2.712+160%1.559+352%
Usd Dividend Per Share----0%-0%-0%0.002-100%
Usd Eps---1.065-0.947-11%-0.517-51%-0.478-55%-0.275-74%
Usd Free Cash Flow---38048000.000-46267000.000+22%-23658750.000-38%-20027050.000-47%-11824318.300-69%
Usd Free Cash Flow Per Share---0.606-0.737+22%-0.377-38%-0.319-47%-0.188-69%
Usd Free Cash Flow To Equity Per Share--2.5630.162+1485%0.907+183%0.298+760%0.166+1448%
Usd Market Cap916406960.000-49%1367078328.0001354995565.000+1%1251899782.000+9%822826745.160+66%558178301.009+145%
Usd Price Per Share14.600-49%21.78021.588+1%19.945+9%13.109+66%8.893+145%
Usd Profit---66860000.000-59407250.000-11%-31361000.000-53%-29753700.000-55%-17154525.000-74%
Usd Revenue--72000.00078500.000-8%443000.000-84%528000.000-86%828625.000-91%
Usd Total Gains Per Share--2.5240.187+1250%0.826+206%0.311+711%0.178+1321%
 EOD+2 -6MRQTTM+24 -9YOY+18 -155Y+20 -1310Y+19 -17

4.2. Fundamental Score

Let's check the fundamental score of Viridian Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-3.427
Price to Book Ratio (EOD)Between0-12.073
Net Profit Margin (MRQ)Greater than0-928.611
Operating Margin (MRQ)Greater than0-915.889
Quick Ratio (MRQ)Greater than131.989
Current Ratio (MRQ)Greater than118.265
Debt to Asset Ratio (MRQ)Less than10.099
Debt to Equity Ratio (MRQ)Less than10.110
Return on Equity (MRQ)Greater than0.15-0.151
Return on Assets (MRQ)Greater than0.05-0.136
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Viridian Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5029.641
Ma 20Greater thanMa 5016.417
Ma 50Greater thanMa 10017.712
Ma 100Greater thanMa 20018.834
OpenGreater thanClose15.090
Total2/5 (40.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Accumulated Other Comprehensive Income  -390216-1741-173109-64402338



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets490,424
Total Liabilities48,402
Total Stockholder Equity442,022
 As reported
Total Liabilities 48,402
Total Stockholder Equity+ 442,022
Total Assets = 490,424

Assets

Total Assets490,424
Total Current Assets486,478
Long-term Assets3,946
Total Current Assets
Cash And Cash Equivalents 102,827
Short-term Investments 374,543
Net Receivables 102
Other Current Assets 9,006
Total Current Assets  (as reported)486,478
Total Current Assets  (calculated)486,478
+/-0
Long-term Assets
Property Plant Equipment 3,342
Long-term Assets Other 604
Long-term Assets  (as reported)3,946
Long-term Assets  (calculated)3,946
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities26,635
Long-term Liabilities21,767
Total Stockholder Equity442,022
Total Current Liabilities
Short-term Debt 843
Accounts payable 2,239
Other Current Liabilities 23,265
Total Current Liabilities  (as reported)26,635
Total Current Liabilities  (calculated)26,347
+/- 288
Long-term Liabilities
Long term Debt 20,205
Capital Lease Obligations 843
Long-term Liabilities Other 989
Long-term Liabilities  (as reported)21,767
Long-term Liabilities  (calculated)22,037
+/- 270
Total Stockholder Equity
Common Stock540
Retained Earnings -725,908
Accumulated Other Comprehensive Income 338
Other Stockholders Equity 960,536
Total Stockholder Equity (as reported)442,022
Total Stockholder Equity (calculated)235,506
+/- 206,516
Other
Capital Stock207,056
Cash and Short Term Investments 477,370
Common Stock Shares Outstanding 49,682
Current Deferred Revenue288
Liabilities and Stockholders Equity 490,424
Net Debt -81,779
Net Invested Capital 255,711
Net Working Capital 459,843
Property Plant and Equipment Gross 4,391
Short Long Term Debt Total 21,048



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-31
> Total Assets 
0
0
0
3,673
3,495
10,663
9,525
8,089
15,747
13,094
14,797
12,902
10,796
9,042
7,541
4,259
57,794
50,026
47,081
52,481
86,992
81,887
76,553
66,147
54,950
48,782
38,813
30,262
39,050
33,485
32,833
131,255
122,832
118,202
221,205
203,709
183,165
169,814
440,580
435,091
386,642
351,467
328,757
490,424
490,424328,757351,467386,642435,091440,580169,814183,165203,709221,205118,202122,832131,25532,83333,48539,05030,26238,81348,78254,95066,14776,55381,88786,99252,48147,08150,02657,7944,2597,5419,04210,79612,90214,79713,09415,7478,0899,52510,6633,4953,673000
   > Total Current Assets 
0
0
0
2,055
1,586
9,768
8,656
6,785
14,491
11,859
13,605
11,734
9,672
7,966
6,512
4,259
56,939
49,350
46,421
51,868
86,353
81,223
75,752
65,370
54,209
48,080
38,217
29,739
38,341
32,521
31,972
129,611
121,534
115,462
217,940
200,163
179,389
166,151
437,355
424,550
373,858
346,331
323,839
486,478
486,478323,839346,331373,858424,550437,355166,151179,389200,163217,940115,462121,534129,61131,97232,52138,34129,73938,21748,08054,20965,37075,75281,22386,35351,86846,42149,35056,9394,2596,5127,9669,67211,73413,60511,85914,4916,7858,6569,7681,5862,055000
       Cash And Cash Equivalents 
0
0
0
209
105
7,696
6,388
5,119
13,268
10,448
12,124
10,832
8,560
6,501
5,351
3,341
54,273
46,335
42,805
47,441
78,099
43,402
31,700
32,606
18,195
24,007
24,857
24,846
36,103
30,582
30,079
45,897
46,489
27,704
138,875
42,299
30,858
31,293
344,210
155,579
88,515
87,082
111,597
102,827
102,827111,59787,08288,515155,579344,21031,29330,85842,299138,87527,70446,48945,89730,07930,58236,10324,84624,85724,00718,19532,60631,70043,40278,09947,44142,80546,33554,2733,3415,3516,5018,56010,83212,12410,44813,2685,1196,3887,696105209000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
32,860
38,827
29,875
32,844
19,940
8,981
1,999
1,999
0
0
81,742
70,611
81,597
74,937
154,666
144,570
129,914
87,112
268,971
285,343
247,209
201,410
374,543
374,543201,410247,209285,343268,97187,112129,914144,570154,66674,93781,59770,61181,742001,9991,9998,98119,94032,84429,87538,82732,860000000000000000000000
       Net Receivables 
0
0
0
994
1,174
1,359
1,550
1,088
598
581
547
394
490
658
733
524
277
539
635
1,456
4,809
1,198
1,382
24
6
325
979
108
4
248
57
0
1,382
2,051
479
451
522
693
398
102
128
102
102
102
1021021021281023986935224514792,0511,38205724841089793256241,3821,1984,8091,4566355392775247336584903945475815981,0881,5501,3591,174994000
       Other Current Assets 
0
0
0
444
133
469
435
349
295
294
570
321
353
594
366
160
2,389
2,476
2,981
2,971
3,445
3,763
3,843
2,865
3,164
3,808
3,400
2,786
2,234
1,691
1,836
1,972
3,052
4,110
3,649
2,747
3,439
4,251
5,635
6,521
8,616
11,938
10,730
9,006
9,00610,73011,9388,6166,5215,6354,2513,4392,7473,6494,1103,0521,9721,8361,6912,2342,7863,4003,8083,1642,8653,8433,7633,4452,9712,9812,4762,389160366594353321570294295349435469133444000
   > Long-term Assets 
0
0
0
1,618
1,909
895
869
1,304
1,256
1,235
1,192
1,168
1,124
1,076
1,029
170
855
676
660
613
639
664
801
777
741
702
596
523
709
964
861
1,644
1,298
2,740
3,265
3,546
3,776
3,663
3,225
10,541
12,784
5,136
4,918
3,946
3,9464,9185,13612,78410,5413,2253,6633,7763,5463,2652,7401,2981,6448619647095235967027417778016646396136606768551701,0291,0761,1241,1681,1921,2351,2561,3048698951,9091,618000
       Property Plant Equipment 
0
0
0
928
892
860
826
1,214
1,213
1,192
1,177
1,153
1,109
1,061
1,014
170
597
626
610
563
589
614
751
727
691
652
596
523
709
963
860
787
520
1,865
1,808
2,055
2,234
2,154
2,072
2,936
3,058
3,952
3,655
3,342
3,3423,6553,9523,0582,9362,0722,1542,2342,0551,8081,8655207878609637095235966526917277516145895636106265971701,0141,0611,1091,1531,1771,1921,2131,214826860892928000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-170
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
1,335
778
875
1,457
318,131
1,542
1,509
1,153
982
0
1,184
0
0
001,18409821,1531,5091,542318,1311,4578757781,335110000000000000-170000000000000000
> Total Liabilities 
0
0
0
1,646
1,870
2,200
1,995
2,098
2,598
2,151
2,164
2,492
2,457
2,605
2,855
4,585
9,800
8,690
8,096
13,971
14,286
14,216
15,835
14,803
13,994
15,345
15,644
14,508
12,050
12,314
11,791
11,218
16,834
19,290
16,614
15,993
16,523
27,916
31,573
40,027
36,093
35,610
45,181
48,402
48,40245,18135,61036,09340,02731,57327,91616,52315,99316,61419,29016,83411,21811,79112,31412,05014,50815,64415,34513,99414,80315,83514,21614,28613,9718,0968,6909,8004,5852,8552,6052,4572,4922,1642,1512,5982,0981,9952,2001,8701,646000
   > Total Current Liabilities 
0
0
0
1,387
1,714
2,137
1,995
1,989
2,495
2,075
2,114
2,468
2,443
2,597
2,853
4,585
7,279
6,630
6,534
3,897
4,137
4,284
6,833
6,733
6,860
9,148
10,385
10,180
8,661
6,723
7,558
10,674
16,436
16,830
14,339
13,636
14,386
21,388
25,214
33,349
29,588
28,657
23,247
26,635
26,63523,24728,65729,58833,34925,21421,38814,38613,63614,33916,83016,43610,6747,5586,7238,66110,18010,3859,1486,8606,7336,8334,2844,1373,8976,5346,6307,2794,5852,8532,5972,4432,4682,1142,0752,4951,9891,9952,1371,7141,387000
       Short-term Debt 
0
0
0
697
1,009
11
11
80
1,058
1,105
1,105
1,105
1,105
1,105
1,105
1,045
1,974
1,979
1,983
0
0
289
1,291
2,294
3,299
3,970
3,972
3,976
4,283
3,814
5,113
455
355
412
430
520
579
580
564
613
637
802
821
843
8438218026376135645805795204304123554555,1133,8144,2833,9763,9723,9703,2992,2941,291289001,9831,9791,9741,0451,1051,1051,1051,1051,1051,1051,0588011111,009697000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,976
3,977
3,417
4,707
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000004,7073,4173,9773,976000000000000000000000000000
       Accounts payable 
0
0
0
410
16
168
239
255
384
332
195
242
102
94
51
159
1,125
632
409
906
760
461
1,206
571
517
1,232
1,556
1,096
1,629
286
232
670
3,384
2,392
3,731
2,329
2,538
4,061
12,152
14,234
7,872
4,133
3,735
2,239
2,2393,7354,1337,87214,23412,1524,0612,5382,3293,7312,3923,3846702322861,6291,0961,5561,2325175711,2064617609064096321,125159519410224219533238425523916816410000
       Other Current Liabilities 
0
0
0
203
672
1,942
1,746
1,654
94
98
101
103
87
67
48
4
82
82
82
2,991
3,377
82
82
82
82
82
82
100
100
100
100
9,248
12,409
13,738
9,890
10,498
10,981
16,459
12,210
18,214
20,791
23,434
18,403
23,265
23,26518,40323,43420,79118,21412,21016,45910,98110,4989,89013,73812,4099,2481001001001008282828282823,3772,991828282448678710310198941,6541,7461,942672203000
   > Long-term Liabilities 
0
0
0
259
156
63
0
109
103
76
50
24
14
8
2
0
2,521
2,060
1,562
10,074
10,149
9,932
9,002
8,070
7,134
6,197
5,259
4,328
3,389
5,591
4,233
544
398
2,460
2,275
2,357
2,137
6,528
6,359
6,678
6,505
6,953
21,934
21,767
21,76721,9346,9536,5056,6786,3596,5282,1372,3572,2752,4603985444,2335,5913,3894,3285,2596,1977,1348,0709,0029,93210,14910,0741,5622,0602,52102814245076103109063156259000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,585
4,613
4,645
4,677
4,709
0
0
004,7094,6774,6454,6134,5850000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
501
365
1,293
2,275
2,357
1,077
1,943
933
933
0
2,244
0
0
002,24409339331,9431,0772,3572,2751,2933655010000000000000000000000000000000
> Total Stockholder Equity
0
0
0
2,027
1,625
8,463
7,530
5,991
13,149
10,943
12,633
10,410
8,339
6,437
4,686
-326
47,994
41,336
38,985
38,510
72,706
67,671
60,718
51,344
40,956
33,437
23,169
15,754
27,000
21,171
21,042
120,037
105,998
98,912
204,591
187,716
166,642
141,898
409,007
395,064
350,549
315,857
283,576
442,022
442,022283,576315,857350,549395,064409,007141,898166,642187,716204,59198,912105,998120,03721,04221,17127,00015,75423,16933,43740,95651,34460,71867,67172,70638,51038,98541,33647,994-3264,6866,4378,33910,41012,63310,94313,1495,9917,5308,4631,6252,027000
   Common Stock
0
0
0
28
28
38
38
38
75
78
106
106
107
108
108
7
214
215
219
226
302
306
308
308
309
310
312
349
531
531
571
42
72
86
194
239
272
285
402
414
431
436
437
540
540437436431414402285272239194867242571531531349312310309308308306302226219215214710810810710610678753838382828000
   Retained Earnings Total Equity00-611,388-556,325-488,174-442,389-413,484-383,993-358,300-329,354-315,311-297,347-278,8870000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
-411
-447
-483
-517
-555
-600
-645
-692
-739
-786
-834
-881
0
-2,627
-2,697
-2,776
-2,835
-2,878
4
-6
-3
2
11
3
-3,348
-3,374
-3,435
-3,471
-8
-21
-12
-3
-157
-935
-1,077
-940
-390
-174
-173
-64
338
338-64-173-174-390-940-1,077-935-157-3-12-21-8-3,471-3,435-3,374-3,3483112-3-64-2,878-2,835-2,776-2,697-2,6270-881-834-786-739-692-645-600-555-517-483-447-411000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
218,089
242,304
259,786
372,291
412,101
439,187
452,696
709,787
741,067
771,705
792,070
0
0
00792,070771,705741,067709,787452,696439,187412,101372,291259,786242,304218,0890000000000000000000000000000000
   Treasury Stock00000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
28,297
28,637
38,790
39,528
13,148
22,948
23,346
28,207
29,011
29,744
30,396
30,531
30,309
66,674
75,165
81,668
134,712
173,536
174,329
176,395
177,335
178,570
179,937
180,905
183,574
206,059
206,726
212,087
218,089
242,304
259,786
372,291
412,101
439,187
452,696
709,787
741,067
771,705
792,070
807,339
960,536
960,536807,339792,070771,705741,067709,787452,696439,187412,101372,291259,786242,304218,089212,087206,726206,059183,574180,905179,937178,570177,335176,395174,329173,536134,71281,66875,16566,67430,30930,53130,39629,74429,01128,20723,34622,94813,14839,52838,79028,63728,297000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue314
Cost of Revenue-1,322
Gross Profit-1,008-1,008
 
Operating Income (+$)
Gross Profit-1,008
Operating Expense-254,764
Operating Income-254,450-255,772
 
Operating Expense (+$)
Research Development159,765
Selling General Administrative94,999
Selling And Marketing Expenses0
Operating Expense254,764254,764
 
Net Interest Income (+$)
Interest Income16,478
Interest Expense-1,847
Other Finance Cost-748
Net Interest Income15,379
 
Pretax Income (+$)
Operating Income-254,450
Net Interest Income15,379
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-237,734-271,166
EBIT - interestExpense = -237,734
-219,171
-235,887
Interest Expense1,847
Earnings Before Interest and Taxes (EBIT)-235,887-235,887
Earnings Before Interest and Taxes (EBITDA)-235,365
 
After tax Income (+$)
Income Before Tax-237,734
Tax Provision-0
Net Income From Continuing Ops-216,659-237,734
Net Income-237,734
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses254,764
Total Other Income/Expenses Net16,716-15,379
 

Technical Analysis of Viridian Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Viridian Therapeutics Inc. The general trend of Viridian Therapeutics Inc is BEARISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Viridian Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-85.7%) Bearish trend (85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Viridian Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 15.04 < 17.33 < 19.07.

The bearish price targets are: 13.00 > 10.93 > 9.87.

Tweet this
Viridian Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Viridian Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 1/14.
The longshort score for the Moving Averages is -12/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Viridian Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Viridian Therapeutics Inc. The current macd is -0.82057754.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Viridian Therapeutics Inc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Viridian Therapeutics Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Viridian Therapeutics Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Viridian Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartViridian Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Viridian Therapeutics Inc. The current adx is 23.59.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Viridian Therapeutics Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Viridian Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Viridian Therapeutics Inc. The current sar is 16.24.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Viridian Therapeutics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Viridian Therapeutics Inc. The current rsi is 29.64. The current phase is Oversold in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Oversold in bear market: Short-term excessive selling, potential for relief rally. Be cautious, consider taking short-term long positions. +1
  • Trending down: The RSI is trending down. -1
Viridian Therapeutics Inc Daily Relative Strength Index (RSI) ChartViridian Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Viridian Therapeutics Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Viridian Therapeutics Inc price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Viridian Therapeutics Inc Daily Stochastic Oscillator ChartViridian Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Viridian Therapeutics Inc. The current cci is -136.59876387.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Viridian Therapeutics Inc Daily Commodity Channel Index (CCI) ChartViridian Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Viridian Therapeutics Inc. The current cmo is -55.94504356.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Viridian Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartViridian Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Viridian Therapeutics Inc. The current willr is -93.17406143.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Viridian Therapeutics Inc Daily Williams %R ChartViridian Therapeutics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Viridian Therapeutics Inc.

Viridian Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Viridian Therapeutics Inc. The current atr is 0.8895068.

Viridian Therapeutics Inc Daily Average True Range (ATR) ChartViridian Therapeutics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Viridian Therapeutics Inc. The current obv is -1,804,930.

Viridian Therapeutics Inc Daily On-Balance Volume (OBV) ChartViridian Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Viridian Therapeutics Inc. The current mfi is 31.32.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Viridian Therapeutics Inc Daily Money Flow Index (MFI) ChartViridian Therapeutics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Viridian Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-29STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-04BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-07STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-08RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-11ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-18STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-20RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-28RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2023-12-29SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-09CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-10MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-23BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-29DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-01-30DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-31WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-05CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-07STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-12CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-15SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-21STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-26CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-29CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-11CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-13CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-14STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-21SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-02SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-10STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-16BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-19STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Viridian Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Viridian Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5029.641
Ma 20Greater thanMa 5016.417
Ma 50Greater thanMa 10017.712
Ma 100Greater thanMa 20018.834
OpenGreater thanClose15.090
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Viridian Therapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on Viridian Therapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Viridian Therapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Viridian Therapeutics Inc

I send you an email if I find something interesting about Viridian Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Viridian Therapeutics Inc.

Receive notifications about Viridian Therapeutics Inc in your mailbox!